FDA Flexes Its FSMA Muscles, Initiates Mandatory Recall

by Morgan Lewis

Recall notification suggests the agency is ready and willing to use its new, enhanced enforcement authority.

On February 13, the U.S. Food and Drug Administration (FDA) began its first enforcement action under the mandatory recall authority granted by the Food Safety Modernization Act (FSMA). FDA issued a Notification of Opportunity to Initiate a Voluntary Recall (Notification)[1] to Kasel Associates Industries, Inc. for the firm's pet treats.


In the wake of a number of large-scale food contamination outbreaks and recalls, on January 4, 2011, Congress enacted FSMA. Section 206 of FSMA (Federal Food, Drug, and Cosmetic Act (FFDCA) section 423) significantly expanding FDA's enforcement powers over potentially dangerous foods. Under the new law, FDA now has authority to order the mandatory recall of foods for which there is a "reasonable probability" that the articles are "adulterated . . . or misbranded . . . and the use of or exposure to such article[s] will cause serious adverse health consequences or death to humans or animals."[2]

In order to issue such a mandatory recall, FDA must first provide the responsible party with the opportunity to initiate a voluntary recall. If the party does not discontinue distribution and initiate the recall, the Secretary of the U.S. Department of Health and Human Services (HHS) is empowered to order that distribution stop and require a recall.[3] Should the secretary order a recall, the responsible party has the opportunity to request a hearing within two days to contest the order and convince FDA that the product should not be recalled.[4]

Prior to the enactment of FSMA, FDA generally had to rely upon manufacturers' voluntary recall efforts or obtain a court order to remove contaminated or misbranded foods, other than infant formula, from the food supply. With the passage of FSMA, however, FDA was provided one more tool in its arsenal to protect the food supply.

Prior to the section 423 Notification to Kasel, FDA had not flexed its new muscles in this particular area. Rather, it stated that it would reserve this power for "rare instances."

The Kasel Notification

As early as September 2012, Colorado and FDA inspectors had conducted tests on numerous finished and unfinished Kasel pet treat products and extensive environmental testing of Kasel's manufacturing facility. Most of these product and environmental samples tested positive for Salmonella, including food contact surfaces within the facility. In addition, FDA investigators specifically cited issues with the Kasel facility's sanitation and cleanliness, including food and clean-up procedures, pest infestation, and general disrepair of the building, fixtures, physical facilities, and manufacturing equipment.

On October 2, 2012, Kasel recalled one lot of affected products after the inspections by Colorado and FDA officials. On October 16, Colorado officials informed Kasel that two additional products tested positive for Salmonella, and, on October 17, Kasel recalled those products as well. On November 19, 2012, Colorado officials received a positive sample for Salmonella in another Kasel product, and FDA encouraged Kasel to recall the product. Kasel, however, declined to do so. As a result, on December 6, 2012, FDA issued a public health warning to consumers, announcing that products that were found to contain Salmonella were not recalled.

Following its second inspection of the Kasel facility in February 2013, FDA issued the Notification, which detailed Kasel's alleged extensive noncompliance record, its failure to recall contaminated products, the conditions in Kasel's facility, and the widespread Salmonella contamination of its products. The Notification further documented (i) the basis for FDA's determination that Kasel's products were adulterated under the FFDCA and (ii) that a reasonable probability existed that the use of or exposure to the products would cause serious adverse health consequences or death to humans or animals.

The Notification provided Kasel with an opportunity to conduct a voluntary recall of affected products within two days (i.e., requiring Kasel to immediately cease distribution of the affected products and give notice to other parties). The Notification stated that, if Kasel did not voluntarily cease distribution and conduct a recall, FDA may, by order, require the firm to recall the affected products. In response to the Notification, on February 21, FDA released a public notice announcing Kasel was voluntarily recalling all pet treats it manufactured from April 20 through September 19, 2012.[5]


FDA's issuance of the Notification provides another indication that the agency is ready and willing to use its new, enhanced enforcement authority under FSMA. FDA previously has employed another section of FSMA, section 102(b), to suspend the registration of Sunland Inc. due to the alleged presence of Salmonella in its manufacturing facility and in many of its products.[6] FDA's latest letter to Kasel demonstrates that FDA is now embracing the use of another new enforcement tool provided to it under FSMA.

FDA, however, has not abandoned its old ways of operating. It still issued a unilateral public health announcement before resorting to its mandatory recall authority. Unlike mandatory recall situations, FDA does not need to provide parties with any form of process prior to issuing such an announcement. Thus, while FSMA entitles parties to notice and a hearing prior to the initiation of a mandatory recall, the potential significance of this regulatory process will be diminished through FDA's continued use of public health announcements.

FDA's recent action, by itself, is insufficient to gauge the agency's willingness to directly use the mandatory recall authority. However, FDA's letter to Kasel indicates it will use the threat of its mandatory recall authority to achieve its objectives. In this case, Kasel was notified of its alleged manufacturing deficiencies multiple times, and it initiated several smaller recalls and was subjected to several inspections. However, it ultimately refused to issue a recall of a scope that would satisfy FDA. The Notification methodically built a case based on the facts to justify FDA's use of section 423 of the FFDCA, clearly laying forth the agency's arguments in anticipation of administrative review should a hearing have been requested.

It is also worth noting that, while FDA warning letters are routinely issued by the agency itself at the working level, the Notification was placed on HHS letterhead and signed by the Deputy Commissioner for Foods and Veterinary Medicine, Michael Taylor.

While the facts and circumstances surrounding the Notification are very specific, FDA did not shy away from the opportunity to use its new enforcement authority when it had a significant record of what it deemed to be noncompliance. However, it is too early to tell whether the agency will indeed use this new authority for only rare instances.

The flexing of FDA's administrative muscles in this particular area, along with what appears to be willingness to pursue food companies criminally, as shown by the recent indictments against the Peanut Corporation of America and its senior executives, should be seen as a clear signal to the food industry that it can be hazardous to take its food safety obligations lightly in the new FSMA environment.

[1]. View the Notification here.

[2]. FFDCA § 423(a).

[3]. FFDCA § 423(b)(1).

[4]. FFDCA § 423(c).

[5]. View the public notice here.

[6]. View FDA's letter to Sunland here.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Morgan Lewis | Attorney Advertising

Written by:

Morgan Lewis

Morgan Lewis on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.


JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.